Olivier de BEAUMONT
Olivier de BEAUMONTCHIEF MEDICAL OFFICER
Doctor of Pharmacy with a master’s degree in management and pharmaceutical marketing, Judith Greciet spent some fifteen years working her way up through subsidiaries of international pharmaceutical companies. She has held major managerial positions with increasing operational and strategic responsibilities from leading sales teams, heading marketing and strategy departments (Pharmacia, Zeneca, LFB, Wyeth France (now Pfizer)) until she finally became President of the French subsidiary of the Japanese laboratory Eisai in June 2007. Throughout her career, Judith Greciet has cultivated a keen awareness of the marketing and business environment of drugs, in France in particular and more broadly in Europe, as well as confronting market access issues, particularly in the areas of oncology and immunology with innovative products such as Enbrel (rheumatology).
Appointed Chief Executive Officer of Onxeo in 2011 (BioAlliance Pharma until 2014), Judith Greciet pursued development of the company by remoulding the strategy towards new growth-areas such as oncology.
Her mandate was renewed for 3 years at the annual shareholders’ general meeting of 2017.
Judith GRECIETCHIEF EXECUTIVE OFFICER
He began his career as Deputy Chief Financial Officer at Total in Cameroon in 1990 and then as Financial Auditor at Ernst & Young on various missions in the industrial and financial sectors.
He then moved to the pharmaceutical industry where, from 1996 to 2006, he held positions of increasing responsibility within the finance division of Pfizer France: first in charge of the treasury and internal audit as Director of Treasury, Tax and Audit. In this position, he was responsible in particular for financial risk management for the French subsidiaries of Pfizer and he managed the financial implementation of various restructuring operations (including two mergers, one with Warner-Lambert in 2000 and then Pharmacia in 2003) as well as the implementation of tax and financial optimisation schemes.
Nicolas Fellmann is a graduate of Lyon Graduate School of Management (EM Lyon).
Nicolas FELLMANNCHIEF FINANCIAL OFFICER
Philippe Maitre has more than 35 years of experience in the pharmaceutical and biotech industry, including nearly 15 years as Corporate Officer for US public companies.
Mr. Maitre has served as Chief Executive Officer and Co-Founder of mAbRx, a biotech company developing monoclonal antibodies against cancer stem cells in partnership with the Duke Cancer Center. Prior to founding mAbRx, Philippe was the Chief Executive Officer at Anosys, a cancer vaccine company spin-off from Aventis (today Sanofi). He has also served as a Chief Financial Officer for NASDAQ-listed companies Pharmaceutical Product Development Inc. (PPD Inc.) and Oscient Pharmaceuticals.
Earlier in his career, Mr. Maitre served in various roles such as finance, business development, and investor relations at companies Rhone Poulenc, Rhone Poulenc Rorer, and Aventis, where he ultimately held the position of Senior Partner and Deputy CFO for Aventis Pharma Group.
Prior to joining the Pharma Industry, Mr. Maitre served in the French Ministry of Foreign Affairs where he was stationed in Libya. He earned his master’s in Finance from the Hautes Etudes de Commerce (HEC) Business School in Paris.
Philippe MAITREEXECUTIVE VICE PRESIDENT - US OPERATIONS - BD
Audrey Legentil-Duméry worked as a Senior HR consultant with a Paris-based agency, managing HR on behalf of diverse companies, notably accompanying SME’s through periods of growth and transition.
Ms. Legentil-Duméry successfully conducted several missions in the pharma and biotech sectors.
Audrey Legentil-Duméry holds a Magister and a Master in Management and Intercultural Communication from CELSA (Sorbonne, Paris).